search
Back to results

Human Milk Oligosaccharides and Childhood Diarrhoea

Primary Purpose

Acute Diarrhea

Status
Completed
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
Oral rehydration solution
Zinc
Human milk oligosaccharides
Breastfeeding
Sponsored by
Société des Produits Nestlé (SPN)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Acute Diarrhea focused on measuring Children, Diarrhea, Human milk oligosaccharides

Eligibility Criteria

6 Months - 2 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Non breast-fed children (group I and group II):

  1. Both male and female children between the ages of 6 months to 2 years.
  2. Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
  3. Guardian is willing to have the child admitted to the hospital as an inpatient until resolution of diarrhea and to return to the clinic with the child on Day 14 after admission for a final evaluation.
  4. Written informed consent must be obtained prior to admission to this study.
  5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.

Exclusion Criteria: Non breast-fed children (group I and group II):

  1. Children of either sex who are fully or partially breast-fed until one week before enrolment (since breastfed children receive naturally HMO, their inclusion into the ORS/zinc or HMO/ORS/zinc arms would critically interfere with the study question; depending on children's age 30 to 50 % of mothers would do so at icddr,b). However, an unblinded reference group will be constituted by age-matched children who are breastfed at the moment of hospitalization for acute diarrhea and where the mothers want to continue breastfeeding on the study ward (so breastfeeding is only an exclusion for the randomized groups).
  2. Suspected or confirmed cholera as detected by a positive DF examination in stool collected on admission. (The large volume and quick evacuation of stool could interfere with product presence in the gut)
  3. Symptom duration > 48 hours at screening.
  4. Vomiting severity that is likely to make administration and retention of test product impossible.
  5. Severe malnutrition defined (using z-scores) as: severe stunting (SS; height-for-age z-score < -3.00); severe underweight (SU; weight-for-age z-score < -3.00), and severe wasting (SW; weight-for-height z-score < -3.00), using the World Health Organization reference value. Moderate malnutrition was defined as follows: moderate stunting (height-for-age z-score -3.00 to < -2.00); moderate underweight (weight-for-age z-score -3.00 to < -2.00); and moderate wasting (weight-for-height z-score -3.00 to < -2.00). We considered children as well-nourished if their z-scores for weight-for-age, height-for-age and weight-for-height z-score were form -2.00 to +1.00.

    Children with moderate malnutrition will be enrolled since they develop with higher frequency PD).

  6. Child already receiving antibiotics or anti-motility drugs for this diarrhea episode prior to screening.
  7. Children with any food allergy.

Breast-fed children, (Group III - Reference group)

  1. Exclusive Breastfed children Either sex: Male and female
  2. Age 6-12 month
  3. Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc.
  4. Written informed consent must be obtained prior to admission to this study.
  5. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.

Sites / Locations

  • International Center for Diarrheal Disease Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Placebo Comparator

Arm Label

ORS+ZINC

ORS+ZINC+HMO

ORS+ZINC+Breastfeeding

Arm Description

Oral rehydration solution + Zinc

Oral rehydration solution + Zinc + Human milk oligosaccharides

Oral rehydration solution + Zinc + Breastfeeding

Outcomes

Primary Outcome Measures

Improvement (change) of clinical symptoms of diarrhea
Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods.

Secondary Outcome Measures

Stools output
Stools output, expressed as g/kg of body weight (cumulative output)
Weight gain
Adverse events
Daily stool frequency
The number of vomiting
The duration of vomiting
Change in Z-score
The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input

Full Information

First Posted
August 10, 2016
Last Updated
July 22, 2019
Sponsor
Société des Produits Nestlé (SPN)
search

1. Study Identification

Unique Protocol Identification Number
NCT02896465
Brief Title
Human Milk Oligosaccharides and Childhood Diarrhoea
Official Title
Treatment of Acute Childhood Diarrhoea With Human Milk Oligosaccharides and Impact on Gut Micro Biota Dysbiosis and Nutritional Status
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
June 2016 (Actual)
Primary Completion Date
October 2018 (Actual)
Study Completion Date
February 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Société des Produits Nestlé (SPN)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Assessment of the impact of oral Human Milk Oligosaccharides (HMO) application on acute diarrhoea and the development of prolonged and persistent diarrhoea in paediatric patients hospitalized with acute diarrhoea.
Detailed Description
The trial is single site, double blind, randomized of HMO addition (1.5 g /day) to standard of care in paediatric diarrhoea patients. HMO application and follow-up of the children at home will be done for 2 weeks. Control patients receive only the standard of care (ORS plus zinc). A breastfed group of diarrhoea patients will serve as reference group. The total sample size is 495 patients. Patients will be females and males aged 6 months to 2 years old with acute diarrhoea.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Diarrhea
Keywords
Children, Diarrhea, Human milk oligosaccharides

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
435 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ORS+ZINC
Arm Type
Active Comparator
Arm Description
Oral rehydration solution + Zinc
Arm Title
ORS+ZINC+HMO
Arm Type
Experimental
Arm Description
Oral rehydration solution + Zinc + Human milk oligosaccharides
Arm Title
ORS+ZINC+Breastfeeding
Arm Type
Placebo Comparator
Arm Description
Oral rehydration solution + Zinc + Breastfeeding
Intervention Type
Other
Intervention Name(s)
Oral rehydration solution
Other Intervention Name(s)
ORS
Intervention Type
Other
Intervention Name(s)
Zinc
Intervention Type
Other
Intervention Name(s)
Human milk oligosaccharides
Other Intervention Name(s)
HMO
Intervention Type
Other
Intervention Name(s)
Breastfeeding
Primary Outcome Measure Information:
Title
Improvement (change) of clinical symptoms of diarrhea
Description
Passage of the last abnormal stool prior to formed/ soft stools during two consecutive 8-hour periods.
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7
Secondary Outcome Measure Information:
Title
Stools output
Description
Stools output, expressed as g/kg of body weight (cumulative output)
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7
Title
Weight gain
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Title
Adverse events
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7, Day14
Title
Daily stool frequency
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7
Title
The number of vomiting
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7
Title
The duration of vomiting
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7
Title
Change in Z-score
Time Frame
Day1, Day14
Title
The amount of ORS to correct dehydration expressed as ml ORS /kg body weight, daily and cumulative input
Time Frame
Day1, Day2, Day3, Day4, Day5, Day6, Day7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Non breast-fed children (group I and group II): Both male and female children between the ages of 6 months to 2 years. Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc. Guardian is willing to have the child admitted to the hospital as an inpatient until resolution of diarrhea and to return to the clinic with the child on Day 14 after admission for a final evaluation. Written informed consent must be obtained prior to admission to this study. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea. Exclusion Criteria: Non breast-fed children (group I and group II): Children of either sex who are fully or partially breast-fed until one week before enrolment (since breastfed children receive naturally HMO, their inclusion into the ORS/zinc or HMO/ORS/zinc arms would critically interfere with the study question; depending on children's age 30 to 50 % of mothers would do so at icddr,b). However, an unblinded reference group will be constituted by age-matched children who are breastfed at the moment of hospitalization for acute diarrhea and where the mothers want to continue breastfeeding on the study ward (so breastfeeding is only an exclusion for the randomized groups). Suspected or confirmed cholera as detected by a positive DF examination in stool collected on admission. (The large volume and quick evacuation of stool could interfere with product presence in the gut) Symptom duration > 48 hours at screening. Vomiting severity that is likely to make administration and retention of test product impossible. Severe malnutrition defined (using z-scores) as: severe stunting (SS; height-for-age z-score < -3.00); severe underweight (SU; weight-for-age z-score < -3.00), and severe wasting (SW; weight-for-height z-score < -3.00), using the World Health Organization reference value. Moderate malnutrition was defined as follows: moderate stunting (height-for-age z-score -3.00 to < -2.00); moderate underweight (weight-for-age z-score -3.00 to < -2.00); and moderate wasting (weight-for-height z-score -3.00 to < -2.00). We considered children as well-nourished if their z-scores for weight-for-age, height-for-age and weight-for-height z-score were form -2.00 to +1.00. Children with moderate malnutrition will be enrolled since they develop with higher frequency PD). Child already receiving antibiotics or anti-motility drugs for this diarrhea episode prior to screening. Children with any food allergy. Breast-fed children, (Group III - Reference group) Exclusive Breastfed children Either sex: Male and female Age 6-12 month Acute diarrhoea (<48 hours) without interfering co-morbidities, e.g. acute respiratory tract infection, sepsis, gross electrolyte imbalances etc. Written informed consent must be obtained prior to admission to this study. The subject has a physical examination that reveals no clinically significant abnormalities other than those expected for subjects with acute infectious diarrhea.
Facility Information:
Facility Name
International Center for Diarrheal Disease Research
City
Dhaka
Country
Bangladesh

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Human Milk Oligosaccharides and Childhood Diarrhoea

We'll reach out to this number within 24 hrs